1-5 of 5
Wim van Putten, MsC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission

Jurjen Versluis, MD, Carin L.E. Hazenberg, MD, Wim van Putten, MSc, Jakob R Passweg, MD, Johan Maertens, MD PhD, Bart J Biemond, MD PhD, Harry C Schouten, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MDPhD, Edo Vellenga, MDPhD, Jan J Cornelissen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 321.
https://doi.org/10.1182/blood.V124.21.321.321
Published: 2014
Journal Articles

The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3 -ITD Allelic Ratio

Jurjen Versluis, MD, Raynier Devillier, MD, Florentien in 't Hout, MD, Wim van Putten, MSc, Markus G Manz, MD, Marie-Christianne Vekemans, MD, Martyn Ronald Schaafsma, MDPhD, Jakob R Passweg, MD, Johan Maertens, MD PhD, Jurgen H Kuball, MDPhD, Leo F. Verdonck, MD PhD, Bart J Biemond, MD, Peter J.M. Valk, PhD, Marie-Joelle Mozziconacci, MD PhD, Norbert Vey, MD PhD, Harry C Schouten, MDPhD, Edo Vellenga, MDPhD, Thomas Pabst, MD, Bob Lowenberg, MDPhD, Gert J Ossenkoppele, MD PhD, Didier Blaise, MD PhD, Gerwin A Huls, MD PhD, Jan J Cornelissen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 323.
https://doi.org/10.1182/blood.V124.21.323.323
Published: 2014
Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 290.
https://doi.org/10.1182/blood.V118.21.290.290
Published: 2011
Journal Articles

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

Pieter Sonneveld, MD, Wim van Putten, MsC, Douwe Biesma, MD, Harald Holte, MD, Marinus van Marwijk Kooij, MD, Mark Henri H. Kramer, MD, P.W. Wijermans, MD, Monique Steijaert, Gustaaf W. van Imhoff, MD, P.J. Lugtenburg, MD, P.C. Huijgens, MD, Mikael Eriksson, MD
Journal: Blood
Blood (2006) 108 (11): 210.
https://doi.org/10.1182/blood.V108.11.210.210
Published: 2006
Journal Articles

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

Pieter Sonneveld, MD, Wim van Putten, MSc, Harald Holte, MD, Douwe Biesma, MD, Marinus van Marwijk-Kooy, MD, Mark Kramer, MD, Pierre Wijermans, MD, Monique Steijaert, Peter Huijgens, MD, Mikael Eriksson, MD
Journal: Blood
Blood (2005) 106 (11): 16.
https://doi.org/10.1182/blood.V106.11.16.16
Published: 2005